Lacosamide Modified Release Formulation for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of lacosamide for epilepsy and migraine treatment have peak-valley plasma concentration profiles that can lead to adverse effects and require frequent dosing, which can disrupt sleep and reduce patient compliance.
Innovation Solution
A modified release formulation of lacosamide using a polymer-based delivery system that controls the release of the drug to maintain therapeutic levels for at least 12 hours, reducing peak-to-trough variation and allowing for once-daily administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation is used, then rapid onset of action is achieved, but frequent dosing is required which disrupts sleep and reduces patient compliance
Solution Approach 1:
The patent applies dynamics by transitioning from a static immediate-release formulation to a dynamic modified-release formulation that adapts drug release over time. The formulation provides rapid initial release for quick onset of action, then transitions to sustained release to maintain therapeutic levels throughout the day and night, eliminating the need for frequent dosing and improving patient compliance.
Solution Approach 2:
The modified-release formulation ensures continuity of useful action by maintaining therapeutic drug levels continuously from administration through the next day. This continuous release profile prevents the peak-valley fluctuations of immediate-release formulations, keeping the drug effective throughout waking hours and during sleep without requiring repeated dosing.
2Speed
If immediate release formulation is used, then rapid onset of action is achieved, but peak-valley plasma concentration profile leads to adverse effects
Solution Approach 1:
The formulation uses dynamics to create a biphasic release profile that is rapid initially for quick onset, then transitions to a controlled sustained release phase. This dynamic release pattern avoids the sharp peaks and valleys of immediate-release formulations, maintaining plasma concentrations within the therapeutic window and minimizing adverse effects associated with high peak concentrations.
Solution Approach 2:
The patent applies parameter changes by modifying the release rate parameter over time. The formulation changes from a high release rate at administration (providing rapid onset) to a lower sustained release rate (maintaining steady levels). This temporal variation in release parameters prevents excessive peak concentrations that cause adverse effects while still achieving rapid therapeutic action.
3Reliability
If frequent dosing is required, then therapeutic levels are maintained, but patient compliance and quality of life are reduced
Solution Approach 1:
The modified-release formulation ensures continuous therapeutic action throughout the dosing interval, maintaining reliable therapeutic levels without requiring frequent administration. The sustained release mechanism keeps drug concentrations within the therapeutic window from a single dose, eliminating the need for multiple daily doses and significantly improving patient compliance and quality of life.
Solution Approach 2:
The formulation uses partial action by providing sufficient drug release to maintain therapeutic levels throughout the extended dosing interval. Rather than requiring full dosing frequency, the modified-release formulation achieves reliable therapeutic maintenance with reduced dosing frequency, improving ease of operation while preserving treatment effectiveness.
Data Source
AI summary
The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.